Tofersen approved by the MHRA to treat rare inherited form of motor neurone disease
The Medicines and Healthcare products Regulatory Agency (MHRA) approved tofersen (Qalsody) on 22 July 2025 to treat adults with amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 (an…